Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors (NASDAQ:CADL)

Candel Therapeutics offers strong risk-reward potential with robust multi-cancer drug data, solid finances, and FDA Fast Track status. Read more on CADL's Buy rating.